首页 > 最新文献

SLAS Discovery最新文献

英文 中文
Open-source electrophilic fragment screening platform to identify chemical starting points for UCHL1 covalent inhibitors 开源亲电片段筛选平台确定UCHL1共价抑制剂的化学起点。
IF 2.7 4区 生物学 Q2 BIOCHEMICAL RESEARCH METHODS Pub Date : 2024-12-01 Epub Date: 2024-11-30 DOI: 10.1016/j.slasd.2024.100198
Scott B. Ficarro , Zachary H. Marto , Nicholas M. Girardi , Dingyu Deng , Isabella Jaen Maisonet , Guillaume Adelmant , Laura E. Fleming , Mona Sharafi , Isidoro Tavares , Andrew Zhao , HyoJeon Kim , Hyuk-Soo Seo , Sirano Dhe-Paganon , Sara J. Buhrlage , Jarrod A. Marto
Target-based screening of covalent fragment libraries with mass spectrometry has emerged as a powerful strategy to identify chemical starting points for small molecule inhibitors or find new binding pockets on proteins of interest. These libraries span diverse chemical space with a modest number of compounds. Screening covalent fragments against purified protein targets reduces the demands on the mass spectrometer with respect to absolute throughput, detection limit, and dynamic range. Given these relaxed analytical requirements, we sought to develop an open-source, medium-throughput mass spectrometry system for target-based covalent fragment screening. Our platform comprises automated, dual LC desalting columns integrated with electrospray ionization for rapid sample introduction and mass spectrometry detection. The system is operated through a simple Python graphical user interface running on commodity microcontroller boards which allow integration with diverse liquid chromatography and mass spectrometry instruments. We provide scripts for fragment pooling, construction of sample batches, along with routines for data processing and visualization. The system enables primary screening of ∼10,000 covalent fragments per day in pooled format. In a proof-of-concept study we executed primary and secondary screens to identify 27 hit fragments against UCHL1, a deubiquitinating enzyme that is emerging as a drug target of interest across multiple clinical indications. We validated and triaged these covalent compounds through a series of orthogonal biochemical and chemoproteomic assays. The most promising chloroacetamide covalent fragment inhibited UCHL1 activity in vitro (IC50 < 5 µM) and exhibited dose-dependent binding along with good selectivity against 57 cellular DUBs as quantified by activity-based protein profiling.
基于靶标的共价片段文库筛选与质谱已经成为一种强大的策略,以确定小分子抑制剂的化学起点或在感兴趣的蛋白质上找到新的结合口袋。这些文库跨越不同的化学空间,包含少量的化合物。针对纯化蛋白目标筛选共价片段减少了对质谱仪在绝对通量、检测限和动态范围方面的需求。鉴于这些宽松的分析要求,我们寻求开发一种开源的、中等通量的质谱系统,用于基于靶标的共价片段筛选。我们的平台包括自动化,双LC脱盐柱集成电喷雾电离快速样品导入和质谱检测。该系统通过一个简单的python图形用户界面运行在商品微控制器板上,允许与各种液相色谱和质谱仪器集成。我们提供了用于片段池、构建样本批次的脚本,以及用于数据处理和可视化的例程。该系统能够以混合格式每天对~ 10,000个共价片段进行初步筛选。在一项概念验证研究中,我们进行了一次和二次筛选,以确定27个针对UCHL1的命中片段,UCHL1是一种去泛素化酶,正在成为多种临床适应症中感兴趣的药物靶点。我们通过一系列正交生化和化学蛋白质组学分析验证和分类这些共价化合物。最有希望的氯乙酰胺共价片段体外抑制UCHL1活性(IC50)
{"title":"Open-source electrophilic fragment screening platform to identify chemical starting points for UCHL1 covalent inhibitors","authors":"Scott B. Ficarro ,&nbsp;Zachary H. Marto ,&nbsp;Nicholas M. Girardi ,&nbsp;Dingyu Deng ,&nbsp;Isabella Jaen Maisonet ,&nbsp;Guillaume Adelmant ,&nbsp;Laura E. Fleming ,&nbsp;Mona Sharafi ,&nbsp;Isidoro Tavares ,&nbsp;Andrew Zhao ,&nbsp;HyoJeon Kim ,&nbsp;Hyuk-Soo Seo ,&nbsp;Sirano Dhe-Paganon ,&nbsp;Sara J. Buhrlage ,&nbsp;Jarrod A. Marto","doi":"10.1016/j.slasd.2024.100198","DOIUrl":"10.1016/j.slasd.2024.100198","url":null,"abstract":"<div><div>Target-based screening of covalent fragment libraries with mass spectrometry has emerged as a powerful strategy to identify chemical starting points for small molecule inhibitors or find new binding pockets on proteins of interest. These libraries span diverse chemical space with a modest number of compounds. Screening covalent fragments against purified protein targets reduces the demands on the mass spectrometer with respect to absolute throughput, detection limit, and dynamic range. Given these relaxed analytical requirements, we sought to develop an open-source, medium-throughput mass spectrometry system for target-based covalent fragment screening. Our platform comprises automated, dual LC desalting columns integrated with electrospray ionization for rapid sample introduction and mass spectrometry detection. The system is operated through a simple Python graphical user interface running on commodity microcontroller boards which allow integration with diverse liquid chromatography and mass spectrometry instruments. We provide scripts for fragment pooling, construction of sample batches, along with routines for data processing and visualization. The system enables primary screening of ∼10,000 covalent fragments per day in pooled format. In a proof-of-concept study we executed primary and secondary screens to identify 27 hit fragments against UCHL1, a deubiquitinating enzyme that is emerging as a drug target of interest across multiple clinical indications. We validated and triaged these covalent compounds through a series of orthogonal biochemical and chemoproteomic assays. The most promising chloroacetamide covalent fragment inhibited UCHL1 activity in vitro (IC<sub>50</sub> &lt; 5 µM) and exhibited dose-dependent binding along with good selectivity against 57 cellular DUBs as quantified by activity-based protein profiling.</div></div>","PeriodicalId":21764,"journal":{"name":"SLAS Discovery","volume":"29 8","pages":"Article 100198"},"PeriodicalIF":2.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142775432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Varieties of interactions of anti-CD133 aptamers with cell cultures from patient glioblastoma 抗 CD133 嵌合体与胶质母细胞瘤患者细胞培养物之间的各种相互作用。
IF 2.7 4区 生物学 Q2 BIOCHEMICAL RESEARCH METHODS Pub Date : 2024-12-01 Epub Date: 2024-11-17 DOI: 10.1016/j.slasd.2024.100195
Olga Antipova , Valeria Moiseenko , Fatima Dzarieva , Ekaterina Savchenko , Igor Pronin , Galina Pavlova , Alexey Kopylov
Development of aptatheranostics for glioblastoma (GB) requires investigating aptamer interactions with cells. The paper has described flow cytometry (FC) assessment of direct interactions of fluorescent anti-CD133 aptamers with cells, focusing on cell cultures derived from patient GB (CCPGB). Conventional cell lines with different levels of CD133 mRNA, Caco-2 and HCT116, were used to compare interactions with known 2′FY-RNA aptamer A15 and DNA aptamers of Ap and Cs series, labeled with FAM and Cy5. In addition, interactions of certain non-aptameric oligonucleotides were studied. In the case of antibody interactions with cells, FC signals, mean fluorescence intensities (MFIs), correlated with sizable amounts of CD133 mRNA in Caco-2 cells, and CCPGBs 107 and G01. Unexpectedly, MFI per se could not be the solid indicator of specific interactions of aptamer - CD133/cell. Instead, two types of interactions, target CD133-driven and off-target membrane-associated ones, contribute to MFI. The latter was notably observed for CCPGB Sus/fP2 with tiny CD133 mRNA amount. To prove specificity of aptamer - CD133/cell interactions, titration experiments have been performed, revealing half-saturation concentrations of 120±27 for 2′FY-RNA A15 and 180±12 for DNA Cs5 with Caco-2 cells. This knowledge is an essential step to develop aptatheranostics for GB.
开发治疗胶质母细胞瘤(GB)的适配体疗法需要研究适配体与细胞的相互作用。本文介绍了流式细胞术(FC)对荧光抗 CD133 合体与细胞直接相互作用的评估,重点是来自 GB 患者(CCPGB)的细胞培养物。研究人员利用具有不同 CD133 mRNA 水平的传统细胞系 Caco-2 和 HCT116,比较了它们与已知的 2'FY-RNA 嵌合体 A15 以及用 FAM 和 Cy5 标记的 Ap 和 Cs 系列 DNA 嵌合体的相互作用。 此外,还研究了某些非嵌合体寡核苷酸的相互作用。在抗体与细胞相互作用的情况下,FC 信号、平均荧光强度(MFIs)与 Caco-2 细胞、CCPGB 107 和 G01 中大量的 CD133 mRNA 相关。出乎意料的是,MFI 本身并不能作为灵媒-CD133/细胞特异性相互作用的可靠指标。相反,两种类型的相互作用(目标 CD133 驱动的相互作用和非目标膜相关的相互作用)对 MFI 有贡献。在 CD133 mRNA 含量极低的 CCPGB Sus/fP2 中明显观察到了后者。为了证明适配体-CD133/细胞相互作用的特异性,进行了滴定实验,结果显示,2'FY-RNA A15 和 DNA Cs5 与 Caco-2 细胞的半饱和浓度分别为 120±27 和 180±12。这一知识是开发用于 GB 的合体止吐药的重要一步。
{"title":"Varieties of interactions of anti-CD133 aptamers with cell cultures from patient glioblastoma","authors":"Olga Antipova ,&nbsp;Valeria Moiseenko ,&nbsp;Fatima Dzarieva ,&nbsp;Ekaterina Savchenko ,&nbsp;Igor Pronin ,&nbsp;Galina Pavlova ,&nbsp;Alexey Kopylov","doi":"10.1016/j.slasd.2024.100195","DOIUrl":"10.1016/j.slasd.2024.100195","url":null,"abstract":"<div><div>Development of aptatheranostics for glioblastoma (GB) requires investigating aptamer interactions with cells. The paper has described flow cytometry (FC) assessment of direct interactions of fluorescent anti-CD133 aptamers with cells, focusing on cell cultures derived from patient GB (CCPGB). Conventional cell lines with different levels of CD133 mRNA, Caco-2 and HCT116, were used to compare interactions with known 2′FY-RNA aptamer A15 and DNA aptamers of Ap and Cs series, labeled with FAM and Cy5. In addition, interactions of certain non-aptameric oligonucleotides were studied. In the case of antibody interactions with cells, FC signals, mean fluorescence intensities (MFIs), correlated with sizable amounts of CD133 mRNA in Caco-2 cells, and CCPGBs 107 and G01. Unexpectedly, MFI <em>per se</em> could not be the solid indicator of specific interactions of aptamer - CD133/cell. Instead, two types of interactions, target CD133-driven and off-target membrane-associated ones, contribute to MFI. The latter was notably observed for CCPGB Sus/fP2 with tiny CD133 mRNA amount. To prove specificity of aptamer - CD133/cell interactions, titration experiments have been performed, revealing half-saturation concentrations of 120±27 for 2′FY-RNA A15 and 180±12 for DNA Cs5 with Caco-2 cells. This knowledge is an essential step to develop aptatheranostics for GB.</div></div>","PeriodicalId":21764,"journal":{"name":"SLAS Discovery","volume":"29 8","pages":"Article 100195"},"PeriodicalIF":2.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142649938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TGF-β receptor-specific NanoBRET Target Engagement in living cells for high-throughput kinase inhibitor screens 活细胞中的 TGF-β 受体特异性 NanoBRET 靶标参与,用于高通量激酶抑制剂筛选。
IF 2.7 4区 生物学 Q2 BIOCHEMICAL RESEARCH METHODS Pub Date : 2024-12-01 Epub Date: 2024-11-12 DOI: 10.1016/j.slasd.2024.100196
Marius Wits , Nicole Haarmans , Gonzalo Sanchez-Duffhues , Marie-José Goumans
Targeting transforming growth factor-β (TGF-β) receptors is a promising pharmacological approach to normalize aberrant signaling in genetic and non-genetic TGF-β associated diseases including fibrosis, cancer, cardiovascular and musculoskeletal disorders. To identify novel TGF-β receptor kinase inhibitors, methods like in vitro kinase assays, western blot or transcriptional reporter assays are often used for screening purposes. While these methods may have certain advantages, the lack of integration of key features such as receptor specificity, high-throughput capability, and cellular context resemblance remains a major disadvantage. This deficiency could ultimately hinder the translation of study outcomes into later (clinical) stages of drug development. In this study, we introduce an adjusted and optimized live cell NanoBRET Target Engagement (TE)-based method to identify TGF-β receptor specific kinase inhibitors. This comprehensive toolkit contains various TGF-β type I and type II receptors, with corresponding nanoBRET tracers, and disease-related cell lines, including novel non-commercially available materials. The nanoBRET capacity and kinase inhibitory window can be significantly enhanced for functional measurements when stable expression cell lines and substantially low tracer concentrations are used. In addition, this system can be tailored to study TGF-β associated genetic disorders and possibly be used to screen for disease-specific therapeutics. Therefore, the use of this optimized, live cell, antibody-independent nanoBRET Target Engagement assay is highly encouraged for future high-throughput compound screens targeting TGF-β/BMP receptors.
靶向转化生长因子-β(TGF-β)受体是一种很有前景的药理学方法,可使与 TGF-β 相关的遗传性和非遗传性疾病(包括纤维化、癌症、心血管疾病和肌肉骨骼疾病)中的异常信号转导正常化。为鉴定新型 TGF-β 受体激酶抑制剂,通常采用体外激酶测定、Western 印迹或转录报告测定等方法进行筛选。虽然这些方法有一定的优势,但缺乏对受体特异性、高通量能力和细胞环境相似性等关键特征的整合仍是其主要缺点。这一缺陷最终会阻碍研究成果转化到药物开发的后期(临床)阶段。在本研究中,我们介绍了一种经过调整和优化的基于活细胞 NanoBRET Target Engagement (TE) 的方法,用于鉴定 TGF-β 受体特异性激酶抑制剂。这个综合工具包包含各种 TGF-β I 型和 II 型受体、相应的 nanoBRET 示踪剂以及与疾病相关的细胞系,包括新型非商业性材料。当使用稳定表达的细胞系和低浓度示踪剂时,纳米BRET能力和激酶抑制窗口可显著增强功能测量。此外,该系统还可定制用于研究与 TGF-β 相关的遗传疾病,并可能用于筛选疾病特异性疗法。因此,在未来针对 TGF-β/BMP 受体的高通量化合物筛选中,我们非常鼓励使用这种优化的、活细胞的、不依赖抗体的 nanoBRET 靶点接合测定。
{"title":"TGF-β receptor-specific NanoBRET Target Engagement in living cells for high-throughput kinase inhibitor screens","authors":"Marius Wits ,&nbsp;Nicole Haarmans ,&nbsp;Gonzalo Sanchez-Duffhues ,&nbsp;Marie-José Goumans","doi":"10.1016/j.slasd.2024.100196","DOIUrl":"10.1016/j.slasd.2024.100196","url":null,"abstract":"<div><div>Targeting transforming growth factor-β (TGF-β) receptors is a promising pharmacological approach to normalize aberrant signaling in genetic and non-genetic TGF-β associated diseases including fibrosis, cancer, cardiovascular and musculoskeletal disorders. To identify novel TGF-β receptor kinase inhibitors, methods like in vitro kinase assays, western blot or transcriptional reporter assays are often used for screening purposes. While these methods may have certain advantages, the lack of integration of key features such as receptor specificity, high-throughput capability, and cellular context resemblance remains a major disadvantage. This deficiency could ultimately hinder the translation of study outcomes into later (clinical) stages of drug development. In this study, we introduce an adjusted and optimized live cell NanoBRET Target Engagement (TE)-based method to identify TGF-β receptor specific kinase inhibitors. This comprehensive toolkit contains various TGF-β type I and type II receptors, with corresponding nanoBRET tracers, and disease-related cell lines, including novel non-commercially available materials. The nanoBRET capacity and kinase inhibitory window can be significantly enhanced for functional measurements when stable expression cell lines and substantially low tracer concentrations are used. In addition, this system can be tailored to study TGF-β associated genetic disorders and possibly be used to screen for disease-specific therapeutics. Therefore, the use of this optimized, live cell, antibody-independent nanoBRET Target Engagement assay is highly encouraged for future high-throughput compound screens targeting TGF-β/BMP receptors.</div></div>","PeriodicalId":21764,"journal":{"name":"SLAS Discovery","volume":"29 8","pages":"Article 100196"},"PeriodicalIF":2.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142634383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High throughput application of the NanoBiT Biochemical Assay for the discovery of selective inhibitors of the interaction of PI3K-p110α with KRAS 高通量应用NanoBiT生化检测发现PI3K-p110α与KRAS相互作用的选择性抑制剂。
IF 2.7 4区 生物学 Q2 BIOCHEMICAL RESEARCH METHODS Pub Date : 2024-12-01 Epub Date: 2024-11-28 DOI: 10.1016/j.slasd.2024.100197
Mohamed Ismail , Gareth Davies , Graham Sproat , Tiziana Monteverde , Jonathan Tart , Marta Acebrón-García-de-Eulate , Andrea Gohlke , David Hancock , Santosh Adhikari , Sandra Stefanovic-Barrett , David M Smith , Vikki Flemington , Emma S. Gleave-Hanford , Geoffrey A. Holdgate , Jason G. Kettle , Julian Downward
The NanoBiT Biochemical Assay (NBBA) was designed as a biochemical format of the NanoBiT cellular assay, aiming to screen weak protein-protein interactions (PPIs) in mammalian cell lysates. Here we present a High Throughput Screening (HTS) application of the NBBA to screen small molecule and fragment libraries to identify compounds that block the interaction of KRAS-G12D with phosphatidylinositol 3-kinase (PI3K) p110α. This interaction promotes PI3K activity, resulting in the promotion of cell growth, proliferation and survival, and is required for tumour initiation and growth in mouse lung cancer models, whilst having little effect on the health of normal adult mice, establishing the significance of the p110α/KRAS interaction as an oncology drug target. Despite the weak binding affinity of the p110α/KRAS interaction (KD = 3 μM), the NBBA proved to be robust and displayed excellent Z’-factor statistics during the HTS primary screening of 726,000 compounds, which led to the identification of 8,000 active compounds. A concentration response screen comparing KRAS/p110α with two closely related PI3K isoforms, p110δ and p110γ, identified selective p110α-specific compounds and enabled derivation of an IC50 for these hits. We identified around 30 compounds showing greater than 20-fold selectivity towards p110α versus p110δ and p110γ with IC50 < 2 μM. By using Differential Scanning Fluorimetry (DSF) we confirmed several compounds that bind directly to purified p110α. The most potent hits will be followed up by co-crystallization with p110α to aid further elucidation of the nature of the interaction and extended optimisation of these compounds.
NanoBiT生化实验(NBBA)是NanoBiT细胞实验的生化形式,旨在筛选哺乳动物细胞裂解物中的弱蛋白-蛋白相互作用(PPIs)。在这里,我们提出了一个高通量筛选(HTS)应用NBBA筛选小分子和片段文库,以确定阻断KRAS-G12D与磷脂酰肌醇3-激酶(PI3K) p110α相互作用的化合物。这种相互作用促进PI3K活性,从而促进细胞生长、增殖和存活,是小鼠肺癌模型中肿瘤发生和生长所必需的,而对正常成年小鼠的健康影响很小,这表明p110α/KRAS相互作用作为肿瘤药物靶点的意义。尽管p110α/KRAS相互作用的结合亲和力较弱(KD = 3 μM),但在HTS对726,000个化合物的初步筛选中,NBBA被证明是稳健的,并表现出良好的Z′因子统计,最终鉴定出8,000个活性化合物。通过比较KRAS/p110α与两个密切相关的PI3K亚型(p110δ和p110γ)的浓度响应筛选,鉴定出选择性的p110α特异性化合物,并能够推导出这些命中的IC50。我们发现了大约30种化合物对p110α的选择性比p110δ和p110γ高20倍以上,IC50 < 2 μM。通过差示扫描荧光法(DSF),我们确认了几个直接与纯化的p110α结合的化合物。最有效的命中将随后与p110α共结晶,以帮助进一步阐明相互作用的性质和扩展优化这些化合物。
{"title":"High throughput application of the NanoBiT Biochemical Assay for the discovery of selective inhibitors of the interaction of PI3K-p110α with KRAS","authors":"Mohamed Ismail ,&nbsp;Gareth Davies ,&nbsp;Graham Sproat ,&nbsp;Tiziana Monteverde ,&nbsp;Jonathan Tart ,&nbsp;Marta Acebrón-García-de-Eulate ,&nbsp;Andrea Gohlke ,&nbsp;David Hancock ,&nbsp;Santosh Adhikari ,&nbsp;Sandra Stefanovic-Barrett ,&nbsp;David M Smith ,&nbsp;Vikki Flemington ,&nbsp;Emma S. Gleave-Hanford ,&nbsp;Geoffrey A. Holdgate ,&nbsp;Jason G. Kettle ,&nbsp;Julian Downward","doi":"10.1016/j.slasd.2024.100197","DOIUrl":"10.1016/j.slasd.2024.100197","url":null,"abstract":"<div><div>The NanoBiT Biochemical Assay (NBBA) was designed as a biochemical format of the NanoBiT cellular assay, aiming to screen weak protein-protein interactions (PPIs) in mammalian cell lysates. Here we present a High Throughput Screening (HTS) application of the NBBA to screen small molecule and fragment libraries to identify compounds that block the interaction of KRAS-G12D with phosphatidylinositol 3-kinase (PI3K) p110α. This interaction promotes PI3K activity, resulting in the promotion of cell growth, proliferation and survival, and is required for tumour initiation and growth in mouse lung cancer models, whilst having little effect on the health of normal adult mice, establishing the significance of the p110α/KRAS interaction as an oncology drug target. Despite the weak binding affinity of the p110α/KRAS interaction (K<sub>D</sub> = 3 μM), the NBBA proved to be robust and displayed excellent Z’-factor statistics during the HTS primary screening of 726,000 compounds, which led to the identification of 8,000 active compounds. A concentration response screen comparing KRAS/p110α with two closely related PI3K isoforms, p110δ and p110γ, identified selective p110α-specific compounds and enabled derivation of an IC<sub>50</sub> for these hits. We identified around 30 compounds showing greater than 20-fold selectivity towards p110α versus p110δ and p110γ with IC<sub>50</sub> &lt; 2 μM. By using Differential Scanning Fluorimetry (DSF) we confirmed several compounds that bind directly to purified p110α. The most potent hits will be followed up by co-crystallization with p110α to aid further elucidation of the nature of the interaction and extended optimisation of these compounds.</div></div>","PeriodicalId":21764,"journal":{"name":"SLAS Discovery","volume":"29 8","pages":"Article 100197"},"PeriodicalIF":2.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Standards for reporting optical biosensor experiments (STROBE): Improving standards in the reporting of optical biosensor-based data in the literature 光学生物传感器实验报告标准(STROBE):改进文献中基于光学生物传感器的数据报告标准。
IF 2.7 4区 生物学 Q2 BIOCHEMICAL RESEARCH METHODS Pub Date : 2024-12-01 Epub Date: 2024-10-31 DOI: 10.1016/j.slasd.2024.100192
Paul E. Belcher , Anna Moberg , Michael B. Murphy
The number of peer-reviewed publications that feature biosensor data increases every year. A search of PubMed using common technique terminology, including bio-layer interferometry (BLI), surface plasmon resonance (SPR) and grating-coupled interferometry (GCI) generated more than 2500 scientific papers from 2022. Compared to 2009, when David Myszka and Rebecca Rich presented their most recent review of biosensor literature (Rich and Myszka, 2011), this number has nearly doubled. With this increasing number of publications comes an increasing need for standardization of the way biosensor data is reported in journals to allow for replication of the experiments that were performed. Biosensor data is often poorly described in papers which makes it difficult, if not impossible, to replicate the experiment. Critical information typically missing includes sample preparation, method settings, and data evaluation details. We have also found published work in which the authors have failed to report the type of sensor that was used, or which biosensor instrumentation was used. To come to terms with this growing problem, we propose a standardization of the way biosensor data is reported in scientific journals. We call this standard STROBE, standards for reporting optical biosensor experiments.
以生物传感器数据为特色的同行评审出版物数量逐年增加。使用常见的技术术语,包括生物层干涉测量法(BLI)、表面等离子体共振(SPR)和光栅耦合干涉测量法(GCI),在PubMed上进行搜索,结果显示2022年以来发表了2500多篇科学论文。与 2009 年大卫-麦兹卡(David Myszka)和丽贝卡-里奇(Rebecca Rich)发表的最新生物传感器文献综述[1]相比,这一数字几乎翻了一番。随着论文数量的不断增加,人们越来越需要对期刊中生物传感器数据的报告方式进行标准化,以便对所进行的实验进行复制。论文中对生物传感器数据的描述往往很差,这使得复制实验变得很困难,甚至是不可能。通常缺少的关键信息包括样品制备、方法设置和数据评估细节。我们还发现,在已发表的论文中,作者没有报告所使用的传感器类型,也没有报告所使用的生物传感器仪器。为了解决这个日益严重的问题,我们建议对科学杂志中生物传感器数据的报告方式进行标准化。我们将这一标准称为 STROBE,即光学生物传感器实验报告标准。
{"title":"Standards for reporting optical biosensor experiments (STROBE): Improving standards in the reporting of optical biosensor-based data in the literature","authors":"Paul E. Belcher ,&nbsp;Anna Moberg ,&nbsp;Michael B. Murphy","doi":"10.1016/j.slasd.2024.100192","DOIUrl":"10.1016/j.slasd.2024.100192","url":null,"abstract":"<div><div>The number of peer-reviewed publications that feature biosensor data increases every year. A search of PubMed using common technique terminology, including bio-layer interferometry (BLI), surface plasmon resonance (SPR) and grating-coupled interferometry (GCI) generated more than 2500 scientific papers from 2022. Compared to 2009, when David Myszka and Rebecca Rich presented their most recent review of biosensor literature (Rich and Myszka, 2011), this number has nearly doubled. With this increasing number of publications comes an increasing need for standardization of the way biosensor data is reported in journals to allow for replication of the experiments that were performed. Biosensor data is often poorly described in papers which makes it difficult, if not impossible, to replicate the experiment. Critical information typically missing includes sample preparation, method settings, and data evaluation details. We have also found published work in which the authors have failed to report the type of sensor that was used, or which biosensor instrumentation was used. To come to terms with this growing problem, we propose a standardization of the way biosensor data is reported in scientific journals. We call this standard STROBE, standards for reporting optical biosensor experiments.</div></div>","PeriodicalId":21764,"journal":{"name":"SLAS Discovery","volume":"29 8","pages":"Article 100192"},"PeriodicalIF":2.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142565046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A mechanism of action-reflective, dual cell-based bioassay for determining the bioactivity of sclerostin-neutralizing antibodies 反映作用机制的双细胞生物测定法,用于确定硬骨蛋白中和抗体的生物活性。
IF 2.7 4区 生物学 Q2 BIOCHEMICAL RESEARCH METHODS Pub Date : 2024-10-01 Epub Date: 2024-10-09 DOI: 10.1016/j.slasd.2024.100187
Suzhen Wei , Qiang Wu , Chunlai Cao , Zhuoni Yang , Jianrui Shi , Jingqun Huang , Hua He , Yongjie Lai , Jing Li
Osteoporosis is a major threat to the elderly worldwide. The Wnt signaling pathway plays a critical role in bone development and homeostasis. Sclerostin, a Wnt ligand inhibitor, competes with Wnt ligands for low-density lipoprotein receptor-related protein 5 or 6 (LRP5/6) on osteoblasts, thereby suppressing bone formation. Sclerostin-neutralizing monoclonal antibodies (mAbs) have emerged as a potential bone-forming therapy for osteoporosis. A cell-based bioassay which determines the relative activity of a product, related to its mechanism of action, is of great importance from drug discovery to quality control and batch release. Currently used cell-based bioassays for sclerostin-neutralizing mAbs usually use Wnt1 or Wnt3a to stimulate the Wnt pathway; sclerostin is a direct inhibitor of Wnt1 but not Wnt3a. Wnt1 is a highly hydrophobic protein that binds to the producing cell membrane and acts in a juxtacrine manner to stimulate the Wnt pathway in neighboring cells. Bioassays for drugs that induce Wnt1 signaling should be performed in a juxtacrine manner. Here, we present a mechanism of action-reflective, dual cell-based reporter gene assay. In this assay, Wnt1 producer cells are co-cultured with cells containing the Wnt reporter genes, Wnt1 on the producer cells activates the Wnt signaling pathway in the reporter cells that are in direct cell-to-cell contact, and sclerostin-neutralizing mAbs specifically and effectively antagonize the sclerostin-mediated Wnt reporter gene suppression. This bioassay demonstrates good specificity, accuracy, linearity, and precision and is suitable for quality control, stability testing, batch release, and biosimilarity assessment of sclerostin-neutralizing mAbs.
骨质疏松症是全球老年人面临的主要威胁。Wnt 信号通路在骨骼发育和稳态中起着至关重要的作用。硬骨素是一种 Wnt 配体抑制剂,能与 Wnt 配体竞争成骨细胞上的低密度脂蛋白受体相关蛋白 5 或 6(LRP5/6),从而抑制骨形成。硬骨素中和单克隆抗体(mAbs)已成为治疗骨质疏松症的潜在骨形成疗法。以细胞为基础的生物测定可确定产品的相对活性(与其作用机制有关),从药物发现到质量控制和批量生产都非常重要。目前用于硬骨素中和 mAbs 的细胞生物测定通常使用 Wnt1 或 Wnt3a 来刺激 Wnt 通路;硬骨素是 Wnt1 的直接抑制剂,但不是 Wnt3a 的直接抑制剂。Wnt1 是一种高度疏水性蛋白质,它能与产生细胞的细胞膜结合,并以共刺激方式刺激邻近细胞的 Wnt 通路。对诱导 Wnt1 信号传导的药物进行生物测定时,应采用并列方式。在这里,我们提出了一种反映作用机制的双细胞报告基因检测方法。在这种检测方法中,Wnt1 生产者细胞与含有 Wnt 报告基因的细胞共同培养,生产者细胞上的 Wnt1 会激活细胞间直接接触的报告基因细胞中的 Wnt 信号通路,而硬骨蛋白中和 mAbs 能特异性地有效拮抗硬骨蛋白介导的 Wnt 报告基因抑制。该生物测定方法具有良好的特异性、准确性、线性和精密度,适用于硬骨蛋白中和 mAbs 的质量控制、稳定性测试、批量放行和生物相似性评估。
{"title":"A mechanism of action-reflective, dual cell-based bioassay for determining the bioactivity of sclerostin-neutralizing antibodies","authors":"Suzhen Wei ,&nbsp;Qiang Wu ,&nbsp;Chunlai Cao ,&nbsp;Zhuoni Yang ,&nbsp;Jianrui Shi ,&nbsp;Jingqun Huang ,&nbsp;Hua He ,&nbsp;Yongjie Lai ,&nbsp;Jing Li","doi":"10.1016/j.slasd.2024.100187","DOIUrl":"10.1016/j.slasd.2024.100187","url":null,"abstract":"<div><div>Osteoporosis is a major threat to the elderly worldwide. The Wnt signaling pathway plays a critical role in bone development and homeostasis. Sclerostin, a Wnt ligand inhibitor, competes with Wnt ligands for low-density lipoprotein receptor-related protein 5 or 6 (LRP5/6) on osteoblasts, thereby suppressing bone formation. Sclerostin-neutralizing monoclonal antibodies (mAbs) have emerged as a potential bone-forming therapy for osteoporosis. A cell-based bioassay which determines the relative activity of a product, related to its mechanism of action, is of great importance from drug discovery to quality control and batch release. Currently used cell-based bioassays for sclerostin-neutralizing mAbs usually use Wnt1 or Wnt3a to stimulate the Wnt pathway; sclerostin is a direct inhibitor of Wnt1 but not Wnt3a. Wnt1 is a highly hydrophobic protein that binds to the producing cell membrane and acts in a juxtacrine manner to stimulate the Wnt pathway in neighboring cells. Bioassays for drugs that induce Wnt1 signaling should be performed in a juxtacrine manner. Here, we present a mechanism of action-reflective, dual cell-based reporter gene assay. In this assay, Wnt1 producer cells are co-cultured with cells containing the Wnt reporter genes, Wnt1 on the producer cells activates the Wnt signaling pathway in the reporter cells that are in direct cell-to-cell contact, and sclerostin-neutralizing mAbs specifically and effectively antagonize the sclerostin-mediated Wnt reporter gene suppression. This bioassay demonstrates good specificity, accuracy, linearity, and precision and is suitable for quality control, stability testing, batch release, and biosimilarity assessment of sclerostin-neutralizing mAbs.</div></div>","PeriodicalId":21764,"journal":{"name":"SLAS Discovery","volume":"29 7","pages":"Article 100187"},"PeriodicalIF":2.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142402302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recapitulation of NOD/RIPK2 signaling in iPSC-derived macrophages 在 iPSC 衍生的巨噬细胞中重现 NOD/RIPK2 信号。
IF 2.7 4区 生物学 Q2 BIOCHEMICAL RESEARCH METHODS Pub Date : 2024-10-01 Epub Date: 2024-09-26 DOI: 10.1016/j.slasd.2024.100185
Mozhgan Dehghan Harati , Jim King , Simon Langer , Florian Binder , Ralf Heilker
Human induced pluripotent stem cell (iPSC)-derived macrophages (IDMs) present a valuable substitute for monocyte-derived macrophages (MDMs) in order to study inflammation pathways in vitro. Through optimization of an IDM differentiation protocol, a six-fold increase in the production yield of myeloid progenitors was achieved. The derived IDMs were further characterized with respect to nucleotide-binding oligomerization domain (NOD) and receptor-interacting serine/threonine-protein kinase 2 (RIPK2) signaling, a key regulatory pathway for autoimmune diseases. The IDM cells recapitulated MDM biology with respect to the proinflammatory chemokine and inflammatory cytokine fingerprint more closely than THP-1 cells. When assessing RIPK2 modulation effect on tumor necrosis factor α (TNF-α), a cardinal mediator of inflammation, a similar pharmacological effect of RIPK2 inhibitors was observed in IDMs and MDMs. Additionally, IDMs and MDMs displayed a similar transcription and pathway profile in response to NOD1/2 stimulation and pharmacological inhibition of RIPK2. In summary, the enhanced myeloid production yield in the improved IDM differentiation protocol offers new opportunities for utilizing physiologically relevant macrophage models in the context of inflammatory diseases.
人类诱导多能干细胞(iPSC)衍生巨噬细胞(IDMs)是研究体外炎症途径的单核细胞衍生巨噬细胞(MDMs)的重要替代品。通过优化IDM分化方案,髓系祖细胞的产量提高了六倍。研究人员进一步鉴定了衍生的IDM细胞在核苷酸结合寡聚化结构域(NOD)和受体丝氨酸/苏氨酸蛋白激酶2(RIPK2)信号转导方面的特性,后者是自身免疫性疾病的关键调节途径。与 THP-1 细胞相比,IDM 细胞在促炎趋化因子和炎症细胞因子指纹方面更接近于再现了 MDM 的生物学特性。在评估 RIPK2 对肿瘤坏死因子 α(TNF-α)(一种主要的炎症介质)的调节作用时,在 IDMs 和 MDMs 中观察到 RIPK2 抑制剂具有相似的药理作用。此外,IDMs 和 MDMs 对 NOD1/2 刺激和 RIPK2 药物抑制的反应显示出相似的转录和通路特征。总之,改进的IDM分化方案提高了髓细胞的产量,为在炎症性疾病中利用生理学相关的巨噬细胞模型提供了新的机会。
{"title":"Recapitulation of NOD/RIPK2 signaling in iPSC-derived macrophages","authors":"Mozhgan Dehghan Harati ,&nbsp;Jim King ,&nbsp;Simon Langer ,&nbsp;Florian Binder ,&nbsp;Ralf Heilker","doi":"10.1016/j.slasd.2024.100185","DOIUrl":"10.1016/j.slasd.2024.100185","url":null,"abstract":"<div><div>Human induced pluripotent stem cell (iPSC)-derived macrophages (IDMs) present a valuable substitute for monocyte-derived macrophages (MDMs) in order to study inflammation pathways in vitro. Through optimization of an IDM differentiation protocol, a six-fold increase in the production yield of myeloid progenitors was achieved. The derived IDMs were further characterized with respect to nucleotide-binding oligomerization domain (NOD) and receptor-interacting serine/threonine-protein kinase 2 (RIPK2) signaling, a key regulatory pathway for autoimmune diseases. The IDM cells recapitulated MDM biology with respect to the proinflammatory chemokine and inflammatory cytokine fingerprint more closely than THP-1 cells. When assessing RIPK2 modulation effect on tumor necrosis factor α (TNF-α), a cardinal mediator of inflammation, a similar pharmacological effect of RIPK2 inhibitors was observed in IDMs and MDMs. Additionally, IDMs and MDMs displayed a similar transcription and pathway profile in response to NOD1/2 stimulation and pharmacological inhibition of RIPK2. In summary, the enhanced myeloid production yield in the improved IDM differentiation protocol offers new opportunities for utilizing physiologically relevant macrophage models in the context of inflammatory diseases.</div></div>","PeriodicalId":21764,"journal":{"name":"SLAS Discovery","volume":"29 7","pages":"Article 100185"},"PeriodicalIF":2.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142334048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combination screen in multi-cell type tumor spheroids reveals interaction between aryl hydrocarbon receptor antagonists and E1 ubiquitin-activating enzyme inhibitor 在多细胞型肿瘤球体中进行联合筛选,发现芳基烃受体拮抗剂与 E1 泛素激活酶抑制剂之间存在相互作用:芳基烃受体拮抗剂药物组合。
IF 2.7 4区 生物学 Q2 BIOCHEMICAL RESEARCH METHODS Pub Date : 2024-10-01 DOI: 10.1016/j.slasd.2024.100186
Thomas S. Dexheimer , Nathan P. Coussens , Thomas Silvers , Eric M. Jones , Li Chen , Jianwen Fang , Joel Morris , Jeffrey A. Moscow , James H. Doroshow , Beverly A. Teicher
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that regulates genes of drug transporters and metabolic enzymes to detoxify small molecule xenobiotics. It has a complex role in cancer biology, influencing both the progression and suppression of tumors by modulating malignant properties of tumor cells and anti-tumor immunity, depending on the specific tumor type and developmental stage. This has led to the discovery and development of selective AhR modulators, including BAY 2416964 which is currently in clinical trials. To identify small molecule anticancer agents that might be combined with AhR antagonists for cancer therapy, a high-throughput combination screen was performed using multi-cell type tumor spheroids grown from malignant cells, endothelial cells, and mesenchymal stem cells. The AhR selective antagonists BAY 2416964, GNF351, and CH-223191 were tested individually and in combination with twenty-five small molecule anticancer agents. As single agents, BAY 2416964 and CH-223191 showed minimal activity, whereas GNF351 reduced the viability of some spheroid models at concentrations greater than 1 µM. The activity of most combinations aligned well with the single agent activity of the combined agent, without apparent contributions from the AhR antagonist. All three AhR antagonists sensitized tumor spheroids to TAK-243, an E1 ubiquitin-activating enzyme inhibitor. These combinations were active in spheroids containing bladder, breast, ovary, kidney, pancreas, colon, and lung tumor cell lines. The AhR antagonists also potentiated pevonedistat, a selective inhibitor of the NEDD8-activating enzyme E1 regulatory subunit, in several tumor spheroid models. In contrast, the AhR antagonists did not enhance the cytotoxicity of the proteasome inhibitor bortezomib.
芳基烃受体(AhR)是一种配体激活的转录因子,可调节药物转运体和代谢酶的基因,从而对小分子异生物体进行解毒。它在癌症生物学中发挥着复杂的作用,根据具体的肿瘤类型和发育阶段,通过调节肿瘤细胞的恶性特性和抗肿瘤免疫,影响肿瘤的发展和抑制。这导致了选择性 AhR 调节剂的发现和开发,包括目前正在进行临床试验的 BAY 2416964。为了找出可与 AhR 拮抗剂联合用于癌症治疗的小分子抗癌剂,研究人员利用恶性细胞、内皮细胞和间充质干细胞培育的多细胞型肿瘤球体进行了高通量联合筛选。测试了 AhR 选择性拮抗剂 BAY 2416964、GNF351 和 CH-223191 单独使用以及与 25 种小分子抗癌剂联合使用的情况。作为单药,BAY 2416964 和 CH-223191 的活性极低,而 GNF351 在浓度超过 1 µM 时会降低一些球状模型的存活率。大多数组合药剂的活性与单一药剂非常一致,没有明显的 AhR 拮抗剂的作用。所有三种 AhR 拮抗剂都能使肿瘤球体对 E1 泛素激活酶抑制剂 TAK-243 敏感。这些组合对含有膀胱、乳腺、卵巢、肾脏、胰腺、结肠和肺部肿瘤细胞系的球形体具有活性。AhR拮抗剂还能增强pevonedistat(一种NEDD8激活酶E1调节亚基的选择性抑制剂)在几种肿瘤球状模型中的作用。相比之下,AhR拮抗剂没有增强蛋白酶体抑制剂硼替佐米的细胞毒性。
{"title":"Combination screen in multi-cell type tumor spheroids reveals interaction between aryl hydrocarbon receptor antagonists and E1 ubiquitin-activating enzyme inhibitor","authors":"Thomas S. Dexheimer ,&nbsp;Nathan P. Coussens ,&nbsp;Thomas Silvers ,&nbsp;Eric M. Jones ,&nbsp;Li Chen ,&nbsp;Jianwen Fang ,&nbsp;Joel Morris ,&nbsp;Jeffrey A. Moscow ,&nbsp;James H. Doroshow ,&nbsp;Beverly A. Teicher","doi":"10.1016/j.slasd.2024.100186","DOIUrl":"10.1016/j.slasd.2024.100186","url":null,"abstract":"<div><div>The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that regulates genes of drug transporters and metabolic enzymes to detoxify small molecule xenobiotics. It has a complex role in cancer biology, influencing both the progression and suppression of tumors by modulating malignant properties of tumor cells and anti-tumor immunity, depending on the specific tumor type and developmental stage. This has led to the discovery and development of selective AhR modulators, including BAY 2416964 which is currently in clinical trials. To identify small molecule anticancer agents that might be combined with AhR antagonists for cancer therapy, a high-throughput combination screen was performed using multi-cell type tumor spheroids grown from malignant cells, endothelial cells, and mesenchymal stem cells. The AhR selective antagonists BAY 2416964, GNF351, and CH-223191 were tested individually and in combination with twenty-five small molecule anticancer agents. As single agents, BAY 2416964 and CH-223191 showed minimal activity, whereas GNF351 reduced the viability of some spheroid models at concentrations greater than 1 µM. The activity of most combinations aligned well with the single agent activity of the combined agent, without apparent contributions from the AhR antagonist. All three AhR antagonists sensitized tumor spheroids to TAK-243, an E1 ubiquitin-activating enzyme inhibitor. These combinations were active in spheroids containing bladder, breast, ovary, kidney, pancreas, colon, and lung tumor cell lines. The AhR antagonists also potentiated pevonedistat, a selective inhibitor of the NEDD8-activating enzyme E1 regulatory subunit, in several tumor spheroid models. In contrast, the AhR antagonists did not enhance the cytotoxicity of the proteasome inhibitor bortezomib.</div></div>","PeriodicalId":21764,"journal":{"name":"SLAS Discovery","volume":"29 7","pages":"Article 100186"},"PeriodicalIF":2.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142373664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Design considerations when creating a high throughput screen-compatible in vitro model of osteogenesis 创建高通量筛选兼容的体外成骨模型时的设计考虑因素
IF 2.7 4区 生物学 Q2 BIOCHEMICAL RESEARCH METHODS Pub Date : 2024-10-01 Epub Date: 2024-09-21 DOI: 10.1016/j.slasd.2024.100184
Stephanie E. Doyle, Courtney N. Cazzola, Cynthia M. Coleman
Inducing osteogenic differentiation in vitro is useful for the identification and development of bone regeneration therapies as well as modelling bone disorders. To couple in vitro models with high throughput screening techniques retains the assay's relevance in research while increasing its therapeutic impact. Miniaturizing, automating and/or digitalizing in vitro assays will reduce the required quantity of cells, biologic stimulants, culture/output assay reagents, time and cost. This review highlights the design and workflow considerations for creating a high throughput screen-compatible model of osteogenesis, comparing and contrasting osteogenic cell type, assay fabrication and culture methodology, osteogenic induction approach and repurposing existing output techniques.
体外诱导成骨分化有助于确定和开发骨再生疗法以及骨疾病模型。将体外模型与高通量筛选技术相结合,既能保持试验在研究中的相关性,又能提高其治疗效果。体外检测的微型化、自动化和/或数字化将减少所需的细胞、生物刺激剂、培养/输出检测试剂的数量、时间和成本。本综述重点介绍了创建高通量筛选兼容成骨模型的设计和工作流程注意事项,比较和对比了成骨细胞类型、化验制造和培养方法、成骨诱导方法和现有输出技术的再利用。
{"title":"Design considerations when creating a high throughput screen-compatible in vitro model of osteogenesis","authors":"Stephanie E. Doyle,&nbsp;Courtney N. Cazzola,&nbsp;Cynthia M. Coleman","doi":"10.1016/j.slasd.2024.100184","DOIUrl":"10.1016/j.slasd.2024.100184","url":null,"abstract":"<div><div>Inducing osteogenic differentiation <em>in vitro</em> is useful for the identification and development of bone regeneration therapies as well as modelling bone disorders. To couple <em>in vitro</em> models with high throughput screening techniques retains the assay's relevance in research while increasing its therapeutic impact. Miniaturizing, automating and/or digitalizing <em>in vitro</em> assays will reduce the required quantity of cells, biologic stimulants, culture/output assay reagents, time and cost. This review highlights the design and workflow considerations for creating a high throughput screen-compatible model of osteogenesis, comparing and contrasting osteogenic cell type, assay fabrication and culture methodology, osteogenic induction approach and repurposing existing output techniques.</div></div>","PeriodicalId":21764,"journal":{"name":"SLAS Discovery","volume":"29 7","pages":"Article 100184"},"PeriodicalIF":2.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142309323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of an automated 3D high content cell screening platform for organoid phenotyping 开发用于类器官表型的自动化三维高含量细胞筛选平台。
IF 2.7 4区 生物学 Q2 BIOCHEMICAL RESEARCH METHODS Pub Date : 2024-10-01 Epub Date: 2024-09-06 DOI: 10.1016/j.slasd.2024.100182
Suleyman B. Bozal , Greg Sjogren , Antonio P. Costa , Joseph S. Brown , Shannon Roberts , Dylan Baker , Paul Gabriel Jr. , Benjamin T. Ristau , Michael Samuels , William F. Flynn , Paul Robson , Elise T. Courtois

The use of organoid models in biomedical research has grown substantially since their inception. As they gain popularity among scientists seeking more complex and biologically relevant systems, there is a direct need to expand and clarify potential uses of such systems in diverse experimental contexts. Herein we outline a high-content screening (HCS) platform that allows researchers to screen drugs or other compounds against three-dimensional (3D) cell culture systems in a multi-well format (384-well). Furthermore, we compare the quality of robotic liquid handling with manual pipetting and characterize and contrast the phenotypic effects detected by confocal imaging and biochemical assays in response to drug treatment. We show that robotic liquid handling is more consistent and amendable to high throughput experimental designs when compared to manual pipetting due to improved precision and automated randomization capabilities. We also show that image-based techniques are more sensitive to detecting phenotypic changes within organoid cultures than traditional biochemical assays that evaluate cell viability, supporting their integration into organoid screening workflows. Finally, we highlight the enhanced capabilities of confocal imaging in this organoid screening platform as they relate to discerning organoid drug responses in single-well co-cultures of organoids derived from primary human biopsies and patient-derived xenograft (PDX) models. Altogether, this platform enables automated, imaging-based HCS of 3D cellular models in a non-destructive manner, opening the path to complementary analysis through integrated downstream methods.

类器官模型自诞生以来,在生物医学研究中的使用已大幅增加。随着它们在寻求更复杂和生物相关系统的科学家中越来越受欢迎,人们直接需要扩大和明确此类系统在不同实验环境中的潜在用途。在此,我们概述了一种高内涵筛选(HCS)平台,它允许研究人员在多孔格式(384 孔)的三维(3D)细胞培养系统中筛选药物或其他化合物。此外,我们还比较了机器人液体处理与手动移液的质量,并对共聚焦成像和生化分析检测到的药物处理表型效应进行了表征和对比。我们的研究表明,与手动移液相比,机器人液体处理具有更高的精度和自动随机化能力,因此更稳定,更适合高通量实验设计。我们还表明,与评估细胞活力的传统生化检测法相比,基于图像的技术在检测类器官培养物表型变化方面更加灵敏,支持将其整合到类器官筛选工作流程中。最后,我们强调了该类器官筛选平台共焦成像的增强功能,因为它们涉及到在源自原发性人体活检和患者异种移植(PDX)模型的类器官单孔共培养中辨别类器官药物反应。总之,该平台能够以非破坏性的方式对三维细胞模型进行基于成像的自动化 HCS,为通过集成的下游方法进行补充分析开辟了道路。
{"title":"Development of an automated 3D high content cell screening platform for organoid phenotyping","authors":"Suleyman B. Bozal ,&nbsp;Greg Sjogren ,&nbsp;Antonio P. Costa ,&nbsp;Joseph S. Brown ,&nbsp;Shannon Roberts ,&nbsp;Dylan Baker ,&nbsp;Paul Gabriel Jr. ,&nbsp;Benjamin T. Ristau ,&nbsp;Michael Samuels ,&nbsp;William F. Flynn ,&nbsp;Paul Robson ,&nbsp;Elise T. Courtois","doi":"10.1016/j.slasd.2024.100182","DOIUrl":"10.1016/j.slasd.2024.100182","url":null,"abstract":"<div><p>The use of organoid models in biomedical research has grown substantially since their inception. As they gain popularity among scientists seeking more complex and biologically relevant systems, there is a direct need to expand and clarify potential uses of such systems in diverse experimental contexts. Herein we outline a high-content screening (HCS) platform that allows researchers to screen drugs or other compounds against three-dimensional (3D) cell culture systems in a multi-well format (384-well). Furthermore, we compare the quality of robotic liquid handling with manual pipetting and characterize and contrast the phenotypic effects detected by confocal imaging and biochemical assays in response to drug treatment. We show that robotic liquid handling is more consistent and amendable to high throughput experimental designs when compared to manual pipetting due to improved precision and automated randomization capabilities. We also show that image-based techniques are more sensitive to detecting phenotypic changes within organoid cultures than traditional biochemical assays that evaluate cell viability, supporting their integration into organoid screening workflows. Finally, we highlight the enhanced capabilities of confocal imaging in this organoid screening platform as they relate to discerning organoid drug responses in single-well co-cultures of organoids derived from primary human biopsies and patient-derived xenograft (PDX) models. Altogether, this platform enables automated, imaging-based HCS of 3D cellular models in a non-destructive manner, opening the path to complementary analysis through integrated downstream methods.</p></div>","PeriodicalId":21764,"journal":{"name":"SLAS Discovery","volume":"29 7","pages":"Article 100182"},"PeriodicalIF":2.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2472555224000443/pdfft?md5=95bb4a25e3d1035eb2e9758c7aafa3a7&pid=1-s2.0-S2472555224000443-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142156865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
SLAS Discovery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1